Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 334-341

  Eicher, C ^a   Dewerth, A ^a   Thomale, J ^b   Ellerkamp, V ^a   Hildenbrand, S ^a   Warmann, S W ^a   Fuchs, J ^a   Armeanu Ebinger, S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

DNA adducts; Hepatoblastoma; Kinase inhibitor; Sorafenib; Tumour growth; Xenograft

Indexed keywords

CISPLATIN; DOXORUBICIN; IRINOTECAN; SORAFENIB; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYTOSTATIC AGENTS; DNA ADDUCTS; ENZYME ACTIVATION; FEMALE; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873566427     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.539     Document Type: Article

References (24)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26): 4293-4300. (Pubitemid 46630787)
2. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK (2011) P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30(41): 4219-4230.
3. Amran D, Sancho P, Fernandez C, Esteban D, Ramos AM, de Blas E, Gomez M, Palacios MA, Aller P (2005) Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation. Biochim Biophys Acta 1743(3): 269-279. (Pubitemid 40544421)
4. Chen FS, Cui YZ, Luo RC, WüJ, Zhang H (2008) [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 28(9): 1684-1687.
5. Doi I (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67(1): 1-10.
6. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S (2012) Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1(nu) mice. Liver Int 32(4): 574-581.
7. Gollob JA, Wilhelm S, Carter C, Kelley SL (2006) Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33(4): 392-406. (Pubitemid 44142735)
8. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D (2005) The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16(2): 129-136. (Pubitemid 40250607)
9. Liedert B, Pluim D, Schellens J, Thomale J (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34(6): E47.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390.
11. Marsh AM, Lo L, Cohen RA, Feusner JH (2012) Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP. Pediatr Blood Cancer 59(5): 939-940.
12. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361(17): 1662-1670.
13. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74(4): 809-818. (Pubitemid 26117140)
14. Schmid I, Haberle B, Albert MH, CorbacioglüS, Frohlich B, Graf N, Kammer B, Kontny U, Leuschner I, Scheel-Walter HG, Scheurlen W, Werner S, Wiesel T, von Schweinitz D (2012) Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 58(4): 539-544.
15. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A (2004) Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 91(3): 589-598. (Pubitemid 39093583)
16. Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ (2010) An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29(49): 6428-6441.
17. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275(50): 39435-39443. (Pubitemid 32058968)
18. Warmann S, Gohring G, Teichmann B, Geerlings H, Pietsch T, Fuchs J (2003) P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 23(6C): 4607-4611. (Pubitemid 38173874)
19. Warmann SW, Fuchs J, Wilkens L, Gratz KF, von Schweinitz D, Mildenberger H (2001) Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan. Med Pediatr Oncol 37(5): 449-454. (Pubitemid 33029639)
20. Warmann SW, Heitmann H, Teichmann B, Gratz KF, Ruck P, Hunger M, Fuchs J (2005) Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol 22(5): 373-386. (Pubitemid 40993600)
21. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10): 3129-3140.
22. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, LiüL, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19): 7099-7109. (Pubitemid 39331023)
23. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11): 1555-1577.
24. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G (2010) Successful treatment of childhood high-risk hepatoblastoma with doseintensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 28(15): 2584-2590.